Nalaganje...
Alectinib in RET-rearranged non-small cell lung cancer—Another progress in precision medicine?
RET fusions have been recognized as potential therapeutic targets in advanced non-small cell lung cancer. RET fusion proteins are detected in about 2% of lung adenocarcinomas. Alectinib, a second generation ALK inhibitor, was shown to block growth of cells with RET fusions. Thus alectinib should be...
Shranjeno v:
| izdano v: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4700226/ https://ncbi.nlm.nih.gov/pubmed/26798590 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.03.08 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|